How Does Microgynon Work in the Body
Chemical Composition, Mechanism of Action & Metabolic Effects Explained
Key Takeaways: How Microgynon Works
- Active Ingredients: Levonorgestrel 150 mcg (progestogen) and ethinylestradiol 30 mcg (oestrogen).
- Primary Actions: Prevents ovulation, thickens cervical mucus to block sperm, and alters the endometrium to inhibit implantation.
- Onset & Duration: Immediate contraceptive protection if started on day 1 of cycle; 24‑hour coverage with each daily pill.
- Metabolism: Both hormones metabolised in the liver via CYP3A4; half‑life ~24 h (levonorgestrel) and ~15 h (ethinylestradiol).
- Important Risks: Small increased risk of venous thromboembolism (5–7 per 10,000 women per year) and breast cancer; does not protect against STIs.
Microgynon is a combined oral contraceptive pill that uses two hormones to prevent pregnancy by suppressing ovulation, altering cervical mucus, and changing the endometrial lining. This guide explains the pharmacological mechanisms in detail.
Important Medical Advice
Seek urgent medical attention if you experience: sudden swelling or pain in one leg, sudden chest pain or breathlessness, severe headache or vision loss, or difficulty speaking – these could be signs of a blood clot. Also stop Microgynon and consult a doctor immediately if you think you may be pregnant or develop jaundice.
Chemical Composition & Molecular Structure
Microgynon 30 ED (Every Day) tablets contain two active steroid hormones: levonorgestrel and ethinylestradiol. Each beige, sugar‑coated active tablet provides 150 micrograms of levonorgestrel and 30 micrograms of ethinylestradiol. The white tablets in the 7‑day reminder row are inactive (placebo) and contain no hormones.
Structural Details
(8R,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one
A second‑generation progestogen with high progestogenic and anti‑oestrogenic activity. It is a derivative of 19‑nortestosterone and lacks the androgenic side‑chain present in testosterone.
19-nor-17α-pregna-1,3,5(10)-trien-20-yne-3,17-diol
A synthetic oestrogen with an ethinyl group at C17, which slows hepatic metabolism and allows oral activity. It binds to oestrogen receptors throughout the body, regulating gonadotropin secretion.
Key Pharmaceutical Properties
| Property | Levonorgestrel | Ethinylestradiol |
|---|---|---|
| Molecular formula | C₂₁H₂₈O₂ | C₂₀H₂₄O₂ |
| Molecular weight | 312.45 g/mol | 296.40 g/mol |
| Lipophilicity (logP) | 3.8 | 3.67 |
| Protein binding | 97‑99% (SHBG, albumin) | 98% (albumin) |
| Oral bioavailability | ≈100% | ≈45% (first‑pass effect) |
| Receptor affinity | High progestogen | High oestrogen |
🗒️ Pharmaceutical insight: The lactose and sucrose excipients aid tablet stability; the placebo pills allow a regular 28‑day cycle, mimicking the natural menstrual rhythm.
Mechanism of Action: Dual Pathway
Microgynon’s contraceptive efficacy results from three complementary peripheral and central actions:
- Ovulation inhibition: Ethinylestradiol and levonorgestrel synergistically suppress hypothalamic GnRH secretion, reducing pituitary release of FSH and LH. The mid‑cycle LH surge is abolished, preventing follicular rupture.
- Cervical mucus thickening: Levonorgestrel increases the viscosity and spinbarkeit of cervical mucus, creating a physical barrier that impedes sperm penetration. This effect is evident within 4 hours of administration.
- Endometrial alteration: The hormonal milieu renders the endometrium thin, atrophic, and unreceptive to implantation, even in the rare event of fertilisation.
| Feature | Ovulation inhibition | Cervical mucus | Endometrium |
|---|---|---|---|
| Onset of action | Immediate (within cycle) | 4‑6 hours | After several days |
| Primary hormone | Both | Levonorgestrel | Levonorgestrel |
| Duration | 24 h (requires daily dose) | Up to 24 h | Continuous with daily use |
🗒️ Physiological insight: The rapid thickening of cervical mucus explains why a single missed pill can compromise contraceptive protection – sperm can survive in the reproductive tract for up to 5 days.
Absorption & Distribution (Pharmacokinetics)
Following oral administration, both hormones are rapidly and completely absorbed from the gastrointestinal tract.
Absorption
Levonorgestrel reaches peak plasma concentrations within 1‑2 hours; ethinylestradiol peaks at 1‑2 hours. Ethinylestradiol undergoes first‑pass metabolism in the gut wall and liver, reducing its systemic bioavailability to approximately 45%.
Distribution
Levonorgestrel is highly bound to sex hormone‑binding globulin (SHBG) and albumin. Ethinylestradiol induces SHBG synthesis, increasing its own binding capacity. Both hormones distribute into breast milk in small amounts.
Metabolic Effects & Elimination
Levonorgestrel is primarily metabolised by reduction of the A‑ring and hydroxylation, followed by conjugation to glucuronide and sulphate metabolites. CYP3A4 is the main enzyme responsible. The elimination half‑life ranges from 24 to 30 hours, with metabolites excreted in urine (45%) and faeces (32%).
Ethinylestradiol undergoes extensive hepatic metabolism: aromatic hydroxylation (CYP3A4) to 2‑hydroxy‑ethinylestradiol, followed by methylation and conjugation. Enterohepatic circulation may occur. Its half‑life is 12‑18 hours. Metabolites are excreted in urine (40%) and faeces (60%).
⚠️ Metabolic caution: Concomitant use of CYP3A4 inducers (e.g., rifampicin, certain antiepileptics) can reduce contraceptive efficacy. Microgynon also slightly impairs glucose tolerance and may alter lipid profiles (HDL‑C often increases).
Clinical Efficacy in Contraception
With perfect use, the Pearl Index for Microgynon is 0.1‑0.9 pregnancies per 100 woman‑years. Typical use (including occasional missed pills) yields a failure rate of about 2‑3%. Regular daily intake at the same time each day maximises efficacy.
Non‑contraceptive benefits include: regular, lighter, less painful periods; reduced risk of ovarian and endometrial cancer with long‑term use; and improvement in premenstrual symptoms. However, it does not protect against sexually transmitted infections.
Microgynon FAQs
How quickly does Microgynon start working?
If started on the first day of your period, protection is immediate. If started on any other day, use additional contraception (e.g., condoms) for the first 7 days.
What should I do if I miss a pill?
If less than 12 hours late, take it immediately and continue normally. If more than 12 hours late, take the last missed pill, skip earlier ones, and use condoms for 7 days. If pills were missed in the first week and you had unprotected sex, consider emergency contraception.
Can Microgynon cause weight gain?
Some women report mild fluid retention, but large studies show no significant weight gain directly attributable to Microgynon. Any changes are usually small and temporary.
Does Microgynon affect fertility long‑term?
No. After stopping, fertility returns rapidly. Most women ovulate within the first cycle, and there is no delay in conceiving compared to non‑users.
Can I take Microgynon while breastfeeding?
It is not usually recommended during breastfeeding because oestrogen can reduce milk supply. Your doctor can suggest a progestogen‑only alternative.
Need Microgynon with Expert Guidance?
If you are considering Microgynon, a UK‑registered doctor can assess your suitability and provide a prescription online after a confidential consultation.
Secure Prescription & Next-Day Delivery
MHRA‑compliant | GPhC‑registered pharmacy | Discreet packaging | UK‑registered doctors
Start Contraception ConsultationRelated Microgynon Guides
Medical Content Manager
Nabeel is a co-founder, and medical content manager of Chemist Doctor. He works closely with our medical team to ensure the information is accurate and up-to-date.
Medical Doctor
Dr. Feroz is a GMC-registered doctor and a medical reviewer at Chemist Doctor. He oversees acute condition and urgent care guidance.
Medical Director
Usman is a co-founder, and medical director of Chemist Doctor. He leads the organisation's strategic vision, bridging clinical and operational priorities.
Review Date: 17 March 2026
Next Review: 17 September 2026
Published on: 17 March 2026
Last Updated: 17 March 2026